Skip to main content

Advertisement

SpringerLink
Log in

A pilot study of first-line olaratumab, doxorubicin and ifosfamide in patients with metastatic soft tissue sarcoma

  • Short Communication
  • Published:
Cancer Chemotherapy and Pharmacology Aims and scope Submit manuscript

Abstract

Introduction

Olaratumab (O) is a monoclonal antibody that specifically binds PDGFRα. The addition of O to doxorubicin (D) has been approved by the regulatory authorities for metastatic soft tissue sarcoma (MSTS). Since the combination of D + ifosfamide (I) is commonly used in MSTS and is associated with a higher response rate than D alone, it seems reasonable to combine O with the combination of D + I (ODI). We report our preliminary experience with O + D+I in MSTS.

Methods

Between 01/01/2015 and 30/05/2018, 15 patients (pts) with MSTS were treated with ODI as first-line therapy. The treatment protocol consisted of IV D 50 mg/m2 and I 5000 mg/m2, day 1 (3 pts), or D 37.5 mg/m2 and I 3000 mg/m2 days 1–2 (12 pts). O (15 mg/kg) was given IV on days 1, 8, and cycles were repeated every 21 days.

Results

With a median follow up of 16 months, 63 cycles of ODI were given. Objective response was achieved in 4 pts (27%) (CR in 3, PR in 1); 5 pts (33%) remained with stable disease for ≥ 5 mo. Median overall survival was 22 months. Major hematological toxicities (grade 3–4) included: neutropenia—7 pts (47%), and neutropenic fever—3 pts (20%). Non-hematological toxicities included grade 3 diarrheas in 2 pts (13%) after the second cycle. There was no treatment-related mortality.

Conclusion

According to our preliminary experience, adding olaratumab to doxorubicin and ifosfamide is active and its safety profile is comparable to that of doxorubicin and ifosfamide alone in MSTS.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Singer S, Demetri GD, Baldini EH, Fletcher CD (2000) Management of soft-tissue sarcomas: an overview and update. Lancet Oncol 1:75–85

    Article  CAS  Google Scholar 

  2. Ng F, Boucher S, Koh S, Sastry KS, Chase L, Lakshmipathy U, Choong C, Yang Z, Vemuri MC, Rao MS, Tanavde V (2008) PDGF, TGF-beta, and FGF signaling is important for differentiation and growth of mesenchymal stem cells (MSCs): transcriptional profiling can identify markers and signaling pathways important in differentiation of MSCs into adipogenic, chondrogenic, and osteogenic lineages. Blood 112:295–307. https://doi.org/10.1182/blood-2007-07-103697

    Article  CAS  PubMed  Google Scholar 

  3. Chen CY, Liu SH, Chen CY, Chen PC, Chen CP (2015) Human placenta-derived multipotent mesenchymal stromal cells involved in placental angiogenesis via the PDGF-BB and STAT3 pathways. Biol Reprod 93:103. https://doi.org/10.1095/biolreprod.115.131250

    Article  CAS  PubMed  Google Scholar 

  4. Ostman A, Heldin CH (2001) Involvement of platelet-derived growth factor in disease: development of specific antagonists. Adv Cancer Res 80:1–38

    Article  CAS  Google Scholar 

  5. Loizos N, Xu Y, Huber J et al (2005) Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumour xenografts: implications as a potential therapeutic target. Mol Cancer Ther 4:369–379

    CAS  PubMed  Google Scholar 

  6. Tap WD, Jones RL, Van Tine BA, Chmielowski B (2016) Olaratumab and doxorubicin versus doxorubicin alone for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 trial. Lancet 30(388):488–497. https://doi.org/10.1016/S0140-6736(16)30587-6

    Article  CAS  Google Scholar 

  7. Leyvraz S, Zweifel M, Jundt G, Swiss Group for Clinical Cancer Research et al (2006) Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Ann Oncol 17:646–651

    Article  CAS  Google Scholar 

  8. Judson I, Verweij J, Gelderblom H, Hartmann JT (2014) Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial. Lancet Oncol. 15:415–423. https://doi.org/10.1016/S1470-2045(14)70063-4

    Article  CAS  PubMed  Google Scholar 

  9. Ryan CW, Merimsky O, Agulnik M et al (2016) PICASSO III: a phase III, placebo-controlled study of doxorubicin with or without palifosfamide in patients with metastatic soft tissue sarcoma. J Clin Oncol 34:3898–3905. https://doi.org/10.1200/JCO.2016.67.6684

    Article  CAS  PubMed  Google Scholar 

  10. Tap WD, et al (2019) ANNOUNCE: A randomized, placebo (PBO)-controlled, double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in patients (pts) with advanced soft tissue sarcomas (STS). Abstract LBA3. ASCO Meeting, Chicago USA

    Article  Google Scholar 

  11. Le Cesne A, Judson I, Crowther D et al (2000) Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 18:2676–2684

    Article  Google Scholar 

  12. http://fdaaa.trialstracker.net/trial/NCT02659020/

Download references

Author information

Authors and Affiliations

  1. Cancer Center, Emek Medical Center, 21 Yitzhak Rabin Blvd, 1834111, Afula, Israel

    Olga Vornicova & Gil Bar-Sela

  2. Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel

    Nissim Haim & Gil Bar-Sela

  3. Division of Oncology, Rambam Health Care Campus, Haifa, Israel

    Nissim Haim

Authors
  1. Olga Vornicova
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nissim Haim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Gil Bar-Sela
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gil Bar-Sela.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Vornicova, O., Haim, N. & Bar-Sela, G. A pilot study of first-line olaratumab, doxorubicin and ifosfamide in patients with metastatic soft tissue sarcoma. Cancer Chemother Pharmacol 84, 919–923 (2019). https://doi.org/10.1007/s00280-019-03928-w

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00280-019-03928-w

Keywords

Search

Navigation